Advances in RNAi therapies for gastric cancer: Targeting drug resistance and nanoscale delivery
Gastric cancer poses a significant health challenge, and exploring innovative therapeutic strategies is imperative. RNA interference (RNAi) has employed as an important therapeutic strategy for diseases by selectively targeting key pathways involved in diseases pathogenesis. Small interfering RNA (s...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223017250 |
| _version_ | 1797404600400084992 |
|---|---|
| author | Mehrdad Hashemi Rezvaneh Aparviz Marzie Beickzade Mahshid Deldar Abad Paskeh Simin Khorsand Kheirabad Zeinab Khazaei Koohpar Amir Moravej Hossein Dehghani Hamidreza Saebfar Mohammad Arad Zandieh Shokooh Salimimoghadam Mohsen Rashidi Afshin Taheriazam Maliheh Entezari Saeed Samarghandian |
| author_facet | Mehrdad Hashemi Rezvaneh Aparviz Marzie Beickzade Mahshid Deldar Abad Paskeh Simin Khorsand Kheirabad Zeinab Khazaei Koohpar Amir Moravej Hossein Dehghani Hamidreza Saebfar Mohammad Arad Zandieh Shokooh Salimimoghadam Mohsen Rashidi Afshin Taheriazam Maliheh Entezari Saeed Samarghandian |
| author_sort | Mehrdad Hashemi |
| collection | DOAJ |
| description | Gastric cancer poses a significant health challenge, and exploring innovative therapeutic strategies is imperative. RNA interference (RNAi) has employed as an important therapeutic strategy for diseases by selectively targeting key pathways involved in diseases pathogenesis. Small interfering RNA (siRNA), a potent RNAi tool, possesses the capability to silence genes and downregulate their expression. This review provides a comprehensive examination of the potential applications of small interfering RNA (siRNA) and short hairpin RNA (shRNA), supplemented by an in-depth analysis of nanoscale delivery systems, in the context of gastric cancer treatment. The potential of siRNA to markedly diminish the proliferation and invasion of gastric cancer cells through the modulation of critical molecular pathways, including PI3K, Akt, and EMT, is highlighted. Besides, siRNA demonstrates its efficacy in inducing chemosensitivity in gastric tumor cells, thus impeding tumor progression. However, the translational potential of unmodified siRNA faces challenges, particularly in vivo and during clinical trials. To address this, we underscore the pivotal role of nanostructures in facilitating the delivery of siRNA to gastric cancer cells, effectively suppressing their progression and enhancing gene silencing efficiency. These siRNA-loaded nanoparticles exhibit robust internalization into gastric cancer cells, showcasing their potential to significantly reduce tumor progression. The translation of these findings into clinical trials holds promise for advancing the treatment of gastric cancer patients. |
| first_indexed | 2024-03-09T02:57:22Z |
| format | Article |
| id | doaj.art-b969a08f6748476caca65d962e48cb93 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-09T02:57:22Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-b969a08f6748476caca65d962e48cb932023-12-05T04:14:49ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-12-01169115927Advances in RNAi therapies for gastric cancer: Targeting drug resistance and nanoscale deliveryMehrdad Hashemi0Rezvaneh Aparviz1Marzie Beickzade2Mahshid Deldar Abad Paskeh3Simin Khorsand Kheirabad4Zeinab Khazaei Koohpar5Amir Moravej6Hossein Dehghani7Hamidreza Saebfar8Mohammad Arad Zandieh9Shokooh Salimimoghadam10Mohsen Rashidi11Afshin Taheriazam12Maliheh Entezari13Saeed Samarghandian14Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, IranFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, IranFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, IranDepartment of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, IranFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, IranFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Department of Cell and Molecular Biology, Faculty of Biological Sciences, Tonekabon Branch, Islamic Azad University, Tonekabon, IranFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, IranFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Department of Medical Laboratory Sciences, Islamic Azad University, Tehran Medical Sciences, Tehran, IranEuropean University Association, League of European Research Universities, University of Milan, ItalyDepartment of Food Hygiene and Quality Control, Division of Epidemiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, IranDepartment of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, IranDepartment Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran; The Health of Plant and Livestock Products Research Center, Mazandaran University of Medical Sciences, Sari, Iran; Corresponding author at: Department Pharmacology, Faculty of Medicine, Mazandaran University of Medical Science, Sari, Iran.Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Department of Orthopedics, Faculty of medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Corresponding author at: Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Corresponding author at: Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.Healthy Ageing Research Centre, Neyshabur University of Medical Sciences, Neyshabur, Iran; Corresponding author.Gastric cancer poses a significant health challenge, and exploring innovative therapeutic strategies is imperative. RNA interference (RNAi) has employed as an important therapeutic strategy for diseases by selectively targeting key pathways involved in diseases pathogenesis. Small interfering RNA (siRNA), a potent RNAi tool, possesses the capability to silence genes and downregulate their expression. This review provides a comprehensive examination of the potential applications of small interfering RNA (siRNA) and short hairpin RNA (shRNA), supplemented by an in-depth analysis of nanoscale delivery systems, in the context of gastric cancer treatment. The potential of siRNA to markedly diminish the proliferation and invasion of gastric cancer cells through the modulation of critical molecular pathways, including PI3K, Akt, and EMT, is highlighted. Besides, siRNA demonstrates its efficacy in inducing chemosensitivity in gastric tumor cells, thus impeding tumor progression. However, the translational potential of unmodified siRNA faces challenges, particularly in vivo and during clinical trials. To address this, we underscore the pivotal role of nanostructures in facilitating the delivery of siRNA to gastric cancer cells, effectively suppressing their progression and enhancing gene silencing efficiency. These siRNA-loaded nanoparticles exhibit robust internalization into gastric cancer cells, showcasing their potential to significantly reduce tumor progression. The translation of these findings into clinical trials holds promise for advancing the treatment of gastric cancer patients.http://www.sciencedirect.com/science/article/pii/S0753332223017250Gastric cancerSiRNANanoparticlesGene deliveryCancer therapy |
| spellingShingle | Mehrdad Hashemi Rezvaneh Aparviz Marzie Beickzade Mahshid Deldar Abad Paskeh Simin Khorsand Kheirabad Zeinab Khazaei Koohpar Amir Moravej Hossein Dehghani Hamidreza Saebfar Mohammad Arad Zandieh Shokooh Salimimoghadam Mohsen Rashidi Afshin Taheriazam Maliheh Entezari Saeed Samarghandian Advances in RNAi therapies for gastric cancer: Targeting drug resistance and nanoscale delivery Biomedicine & Pharmacotherapy Gastric cancer SiRNA Nanoparticles Gene delivery Cancer therapy |
| title | Advances in RNAi therapies for gastric cancer: Targeting drug resistance and nanoscale delivery |
| title_full | Advances in RNAi therapies for gastric cancer: Targeting drug resistance and nanoscale delivery |
| title_fullStr | Advances in RNAi therapies for gastric cancer: Targeting drug resistance and nanoscale delivery |
| title_full_unstemmed | Advances in RNAi therapies for gastric cancer: Targeting drug resistance and nanoscale delivery |
| title_short | Advances in RNAi therapies for gastric cancer: Targeting drug resistance and nanoscale delivery |
| title_sort | advances in rnai therapies for gastric cancer targeting drug resistance and nanoscale delivery |
| topic | Gastric cancer SiRNA Nanoparticles Gene delivery Cancer therapy |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223017250 |
| work_keys_str_mv | AT mehrdadhashemi advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT rezvanehaparviz advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT marziebeickzade advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT mahshiddeldarabadpaskeh advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT siminkhorsandkheirabad advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT zeinabkhazaeikoohpar advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT amirmoravej advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT hosseindehghani advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT hamidrezasaebfar advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT mohammadaradzandieh advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT shokoohsalimimoghadam advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT mohsenrashidi advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT afshintaheriazam advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT malihehentezari advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery AT saeedsamarghandian advancesinrnaitherapiesforgastriccancertargetingdrugresistanceandnanoscaledelivery |